H. Cohen
Director/Board Member en Paragon Biosciences LLC .
Fortuna: 491 408 $ al 29/02/2024
Perfil
H.
Michael Cohen is on the board of Paragon Biosciences LLC.
Mr. Cohen received an MBA from The Trustees of Columbia University in The City of New York and an undergraduate degree from the University of Vermont.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
MASIMO CORPORATION
0.01% | 26/05/2023 | 3 823 ( 0.01% ) | 491 408 $ | 29/02/2024 |
Cargos activos de H. Cohen
Empresas | Cargo | Inicio |
---|---|---|
Paragon Biosciences LLC
Paragon Biosciences LLC Miscellaneous Commercial ServicesCommercial Services Paragon Biosciences LLC is a life science innovator that creates, invests in, and builds life science companies in biopharmaceuticals, cell and gene therapy, and synthetic biology utilizing artificial intelligence. Paragon Biosciences is based in Chicago, IL, and has subsidiaries in the United States. The private company's current portfolio includes Castle Creek Biosciences, Circ Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences Holdings, Qlarity Imaging, Skyline Biosciences, and a consistent flow of incubating companies created and supported by the Paragon Innovation Capital™ model. The company's mission is to solve complex human and societal challenges by creating and supporting focused, visionary companies that accelerate the development of novel therapies and life science breakthroughs. The company was founded by Jeffrey S. Aronin, who has been the CEO since incorporation. | Director/Board Member | 01/01/2018 |
Antiguos cargos conocidos de H. Cohen.
Empresas | Cargo | Fin |
---|---|---|
MASIMO CORPORATION | Director/Board Member | 26/06/2023 |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Director/Board Member | - |
Formación de H. Cohen.
The Trustees of Columbia University in The City of New York | Masters Business Admin |
University of Vermont | Undergraduate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
MASIMO CORPORATION | Health Technology |
Empresas privadas | 2 |
---|---|
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Health Technology |
Paragon Biosciences LLC
Paragon Biosciences LLC Miscellaneous Commercial ServicesCommercial Services Paragon Biosciences LLC is a life science innovator that creates, invests in, and builds life science companies in biopharmaceuticals, cell and gene therapy, and synthetic biology utilizing artificial intelligence. Paragon Biosciences is based in Chicago, IL, and has subsidiaries in the United States. The private company's current portfolio includes Castle Creek Biosciences, Circ Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences Holdings, Qlarity Imaging, Skyline Biosciences, and a consistent flow of incubating companies created and supported by the Paragon Innovation Capital™ model. The company's mission is to solve complex human and societal challenges by creating and supporting focused, visionary companies that accelerate the development of novel therapies and life science breakthroughs. The company was founded by Jeffrey S. Aronin, who has been the CEO since incorporation. | Commercial Services |